These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 36172053)

  • 1. Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis.
    Xu M; Fan R; Fan X; Shao Y; Li X
    Drug Des Devel Ther; 2022; 16():3241-3262. PubMed ID: 36172053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges.
    Dervenis N; Mikropoulou AM; Tranos P; Dervenis P
    Adv Ther; 2017 Jun; 34(6):1270-1282. PubMed ID: 28484955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
    Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
    BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
    Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
    Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
    Hussain RM; Ciulla TA
    Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
    Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
    Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
    Krick TW; Bressler NM
    Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological drug therapy for ocular angiogenesis: Anti-VEGF agents and novel strategies based on nanotechnology.
    Formica ML; Awde Alfonso HG; Palma SD
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00723. PubMed ID: 33694304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Borkar DS; Obeid A; Su DC; Storey PP; Gao X; Regillo CD; Kaiser RS; Garg SJ; Hsu J;
    Am J Ophthalmol; 2018 Oct; 194():1-6. PubMed ID: 29981738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
    Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.
    Li Y; Busoy JM; Zaman BAA; Tan QSW; Tan GSW; Barathi VA; Cheung N; Wei JJ; Hunziker W; Hong W; Wong TY; Cheung CMG
    Exp Eye Res; 2018 Sep; 174():98-106. PubMed ID: 29852133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology.
    Ehlers JP; Yeh S; Maguire MG; Smith JR; Mruthyunjaya P; Jain N; Kim LA; Weng CY; Flaxel CJ; Schoenberger SD; Kim SJ
    Ophthalmology; 2022 Jan; 129(1):88-99. PubMed ID: 34446301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
    Ajlan RS; Silva PS; Sun JK
    Semin Ophthalmol; 2016; 31(1-2):40-8. PubMed ID: 26959128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema.
    Kelkar A; Webers C; Shetty R; Kelkar J; Labhsetwar N; Pandit A; Malode M; Tidke S
    Indian J Ophthalmol; 2020 Oct; 68(10):2143-2147. PubMed ID: 32971626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
    Emerson MV; Lauer AK
    BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optical coherence tomography angiography analysis of macular vessel density before and after anti-VEGF therapy in eyes with diabetic retinopathy.
    Sorour OA; Sabrosa AS; Yasin Alibhai A; Arya M; Ishibazawa A; Witkin AJ; Baumal CR; Duker JS; Waheed NK
    Int Ophthalmol; 2019 Oct; 39(10):2361-2371. PubMed ID: 31119505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.